Lipoprotein a: where are we now?
Τίτλος | Lipoprotein a: where are we now? |
Publication Type | Journal Article |
Year of Publication | 2009 |
Authors | Tziomalos, K., Athyros V. G., Wierzbicki A. S., & Mikhailidis D. P. |
Journal | Curr Opin Cardiol |
Volume | 24 |
Issue | 4 |
Pagination | 351-7 |
Date Published | 2009 Jul |
ISSN | 1531-7080 |
Λέξεις κλειδιά | Anticholesteremic Agents, Coronary Artery Disease, Disease Progression, Fibrinolysis, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Inflammation, Lipoprotein(a), Peripheral Vascular Diseases, Risk Assessment, Risk Factors, Stroke |
Abstract | PURPOSE OF REVIEW: To provide an update of the literature describing the link between lipoprotein a and vascular disease.RECENT FINDINGS: There is evidence that elevated plasma lipoprotein a levels are associated with coronary heart disease, stroke and other manifestations of atherosclerosis. Several mechanisms may be implicated, including proinflammatory actions and impaired fibrinolysis.SUMMARY: Lipoprotein a potentially represents a useful tool for risk stratification in the primary and secondary prevention setting. However, there are still unresolved methodological issues regarding the measurement of lipoprotein a levels. Targeting lipoprotein a in order to reduce vascular risk is hampered by the lack of well tolerated and effective pharmacological interventions. Moreover, it has not yet been established whether such a reduction will result in fewer vascular events. The risk attributed to lipoprotein a may be reduced by aggressively tackling other vascular risk factors, such as low-density lipoprotein cholesterol. |
DOI | 10.1097/HCO.0b013e32832ac21a |
Alternate Journal | Curr. Opin. Cardiol. |
PubMed ID | 19417640 |